tbuckley/cabot-search huggingface dataset:
Chikungunya Vaccine Trials Begin
Authors: Jeff Lyon
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Development of CNS metastasis and subsequent survival in patients with inflammatory breast cancer.
Authors: John Thomas French, Kenneth R. Hess, Diane D Liu, Kanwal Pratap Singh Raghav, Gabriel N. Hortobagyi, Banu Arun, Vicente Valero, Naoto T. Ueno, Ricardo H. Alvarez, Wendy A. Woodward, Bisrat G Debeb, Stacy L. Moulder, Bora Lim, Debu Tripathy, Nuhad K. Ibrahim
Journal: Journal of Clinical Oncology (2015)

1586 Background: Inflammatory breast cancer (IBC) is associated with a poor prognosis and high risk of central nervous system (CNS) metastases. We determined the cumulative incidence rate of developing CNS metastasis and overall survival (OS) in stage III IBC patients (pts) compared to pts with non-inflammatory invasive ductal carcinoma (NI-IDC). The purpose of this study was to evaluate the incidence rate of CNS metastasis from 1 year after diagnosis and analyze OS after CNS metastasis occurrence. We also sought to identify prognostic factors using univariate and multivariate competing risk regression models. Methods: We performed a retrospective review using the MD Anderson Cancer Center breast cancer database looking at stage III IDC pts treated between 1/1/1984 and 12/31/2011. For inclusion, pts were required to have initiated primary treatment within one year of their diagnosis and have follow-up for at least 1 year before the development of CNS metastasis or death. Results: 2323 pts were identified (589 IBC and 1734 NI-IDC). 81 IBC pts developed CNS metastasis compared to 154 NI-IDC pts. The 2-, 5-, and 10-year cumulative incidence rates of CNS metastasis in IBC and NI-IDC were 9.8%, 15.8%, and 17.4% and 6.5%, 10.1%, and 12.7%, respectively. This occurrence was significantly different between IBC and NI-IDC pts (p = 0.0037). However, multicovariate competing risk regression models looking at 18 variables in IBC and NI-IDC pts including patient, tumor, and treatment characteristics showed no statistically significant associations with the risk of developing CNS metastasis. In terms of survival, with a median follow up of 7.2 years, median post CNS metastasis OS was not significantly different between IBC (7.6 months) and NI-IDC (5.6 months) pts. At last follow up, 190 pts with CNS metastasis have died. HER2 positive pts had better OS with a median 14.1 months vs 4.3 months (p = < 0.0001). In addition, age > 50 (p = 0.012) but not IBC status (p = 0.49) was a significant predictor of post CNS metastasis survival. Conclusions: IBC pts have a higher incidence rate in the development of brain metastasis but OS following brain metastases is similar to its NI-IDC counterpart. Only HER2 status and age appears to play a role in prognosis.
Epistaxis, Ecchymoses, and an Abnormal White Blood Cell Count
Authors: Meredith H. Sellers, Shira N. Dinner
Journal: JAMA (2017)

A 42-year-old man had epistaxis and spontaneous ecchymoses of the extremities. A complete blood cell count and coagulation profile showed abnormalities, and a peripheral blood smear showing promyelocytes with bilobed nuclei and azurophilic cytoplasmic granules. What would you do next?
Efficacy and safety of eribulin in patients with metastatic breast cancer at early and late application: Real-life experience.
Authors: Valentina Manzyuk, Vera Gorbunova, Elena Kovalenko, Larisa V Bolotina, Tatiana Semiglazova, Dmitry Ponomarenko, Larisa Zhilyaeva, Venera Mukhametshina, Elena Karabina
Journal: Journal of Clinical Oncology (2017)

e12579 Background: We sought to describe treatment patterns of eribulin and clinical outcomes associated with early and late use among anthracycline and taxane-pretreated patients with advanced breast cancer treated in community oncology practices across the Russian Federation. Methods: Patients treated with eribulin anytime between Jan1, 2014 and Jan 1, 2017 with a diagnosis of MBC were identified by providers within the Russia Oncology Research Center. Providers reviewed the health records and abstracted selected data points into an electronic case report form for each eligible patient. Results: A total 113 MBC patients were considered by 16 providers. A median age was 53 (44-58) yrs and ECOG status 0-1 were assessed. 57 (50,5%) pts were ER/PR-positive, 37 (32,7%) – triple-negative, 19 (16,8%) – HER2-positive (in combination with trastuzumab). Most of the pts (96,5%) had visceral mts, a median number metastatic disease regions was 2 (1-3). Eribulin was administered as the 1 st and 2 nd line of MBC treatment to 36 (32%) pts (early application), the 3 rd and later lines (late application) – to 77 (68%) pts. Clinical response rate (ORR and SD ≥ 6 months) was 44% among early line treated patients (first and second-line combined) and 38% among late line eribulin treated patients. Median PFS was 4,89 months (95% CI 2,84-8,00) among early users and 3,96 months (95% CI 2,04-7,99) among later users. The effectiveness in early eribulin application group was higher, but difference was not statistically significant. Tolerability of the drug was good: withdrawn due to toxicity had 3,5%, dose reduction – 13, 3% of pts. The most common type of toxicity was hematological with neutropenia Gr II in 12 (10,6%) of pts and Gr III – in 8 (7,1%) of pts and 2 pts had febrile neutropenia. 6 (5,3%) pts experienced fatigue Gr II. Peripheral neuropathy Gr II was observed in 8 (7,1%) of pts. Conclusions: This is the first real-life description of clinical outcomes, for patients initiating eribulin therapy for MBC throughout the Russian Federation. Our experience with Eribulin in MBC patients confirms it efficacy and safety in early lines of treatment and intensively pretreated patients.
Methods of Academic Course Planning for Cancer Biology PhD Students to Enhance Knowledge of Clinical Oncology
Authors: Malcolm D. Mattes, Elizabeth Swart, Steven M. Markwell, Sijin Wen, Linda C. Vona-Davis
Journal: Cancer Research (2017)

Little is known about how clinical oncology concepts are taught to PhD students or the most effective methods of doing so. In this study, electronic surveys were sent to faculty and students at PhD training programs, assessing their institution's methods of clinical oncology education and their perspective on optimal approaches to clinical oncology education. Only 40.0% of students reported any clinical oncology component to their institution's training, and only 26.5% had a clinician on their graduate advisory committee. Forty-three percent of students believed that they had a good understanding for translating basic science research into clinical practice, and 77.2% of all participants believed dual degree MD/PhD students were superior to PhD students in this regard. Lectures on clinical oncology research topics were the most valuable type of experience for all participants and were also the most common type of experience utilized. Working with a clinician to develop a clinical trial with correlative endpoints was also highly valued, but was only utilized by approximately 10% of programs. Faculty rated the value of nearly all types of clinical oncology exposure significantly lower than did students. Inclusion of the approaches identified in this study is likely to enhance PhD training in oncology-related disciplines. Cancer Res; 77(18); 4741-4. ©2017 AACR.
The efficacy of wrist working splints in patients with rheumatoid arthritis: results of a randomized controlled study
Authors: M.M. Veehof, E. Taal, L.M. Heijnsdijk-Rouwenhorst, M.A.F.J. van de Laar
Journal: Annals of the Rheumatic Diseases (2008)

Background: Wrist working splints are frequently prescribed to rheumatoid arthritis (RA) patients suffering from wrist arthritis. They aim to reduce pain and inflammation, and improve functional ability by providing rest, support and stabilization of the wrist. The effects of this type of splints have not thoroughly been investigated. Objectives: The aim of this study was to examine the efficacy of wrist working splints after a period of splinting in RA patients. Methods: A four-week randomized controlled trial was performed among RA patients with wrist arthritis. Selected patients were randomly allocated to the splinting group or the control group. Patients in the splinting group received a commercially available prefabricated wrist working splint and were instructed to use this splint as much as possible during the day, but especially during the performance of activities. To stimulate adherence with splint wearing, adherence-enhancing strategies, which were established in a former study (1), were included. Primary outcome measure was wrist pain, measured using a visual analogue scale (VAS). Secondary outcome measures were grip strength and functional ability. The latter was measured using the Disabilities of the Arm, Shoulder, and Hand questionnaire (DASH) and the short version of the Sequential Occupational Dexterity Assessment (SODA-S). Measurements were performed at baseline and after four weeks. Differences in change scores between the splinting and the control group were analysed using analyses of covariance with baseline scores of the outcome variable as covariate. To indicate the magnitude of the treatment effects, effect sizes were calculated. Results: A total of 33 patients were enrolled in this study. No significant differences in patient characteristics between the splinting (n=17) and the control (n=16) group were found at baseline. Mean age of the patients in both group was respectively 60.3 (SD 10.8) and 55.1 (SD 12.8) years. Mean DAS28 scores were respectively 4.37 (SD 1.01) and 4.34 (SD 1.33). A large and highly significant treatment effect on wrist pain was found. VAS pain scores decreased with 32% in the splinting group and increased with 17% in the control group. Small and non-significant treatment effects were found with regard to nonsplinted grip strength and functional ability. Conclusion: This randomized controlled study demonstrates that commercially available prefabricated wrist working splints are highly effective in reducing wrist pain after four weeks of splint wearing among RA patients with arthritis of the wrist.
The lncRNA CASC15 regulates SOX4 expression in RUNX1-rearranged acute leukemia
Authors: Thilini R. Fernando, Jorge R. Contreras, Matteo Zampini, Norma I. Rodriguez-Malave, Michael O. Alberti, Jaime Anguiano, Tiffany M. Tran, Jayanth K. Palanichamy, Jasmine Gajeton, Nolan M. Ung, Cody J. Aros, Ella V. Waters, David Casero, Giuseppe Basso, Martina Pigazzi, Dinesh S. Rao
Journal: Molecular Cancer (2017)

Long non-coding RNAs (lncRNAs) play a variety of cellular roles, including regulation of transcription and translation, leading to alterations in gene expression. Some lncRNAs modulate the expression of chromosomally adjacent genes. Here, we assess the roles of the lncRNA CASC15 in regulation of a chromosomally nearby gene, SOX4, and its function in RUNX1/AML translocated leukemia. CASC15 is a conserved lncRNA that was upregulated in pediatric B-acute lymphoblastic leukemia (B-ALL) with t (12; 21) as well as pediatric acute myeloid leukemia (AML) with t (8; 21), both of which are associated with relatively better prognosis. Enforced expression of CASC15 led to a myeloid bias in development, and overall, decreased engraftment and colony formation. At the cellular level, CASC15 regulated cellular survival, proliferation, and the expression of its chromosomally adjacent gene, SOX4. Differentially regulated genes following CASC15 knockdown were enriched for predicted transcriptional targets of the Yin and Yang-1 (YY1) transcription factor. Interestingly, we found that CASC15 enhances YY1-mediated regulation of the SOX4 promoter. Our findings represent the first characterization of this CASC15 in RUNX1-translocated leukemia, and point towards a mechanistic basis for its action.
Implementation of a Model-Based Design in a Phase Ib Study of Combined Targeted Agents
Authors: Nolan A. Wages, Craig A. Portell, Michael E. Williams, Mark R. Conaway, Gina R. Petroni
Journal: Clinical Cancer Research (2017)

Abstract In recent years, investigators have recognized the rigidity of single-agent, safety-only, traditional designs, rendering them ineffective for conducting contemporary early-phase clinical trials, such as those involving combinations and/or biological agents. Novel approaches are required to address these research questions, such as those posed in trials involving targeted therapies. We describe the implementation of a model-based design for identifying an optimal treatment combination, defined by low toxicity and high efficacy, in an early-phase trial evaluating a combination of two oral targeted inhibitors in relapsed/refractory mantle cell lymphoma. Operating characteristics demonstrate the ability of the method to effectively recommend optimal combinations in a high percentage of trials with reasonable sample sizes. The proposed design is a practical, early-phase, adaptive method for use with combined targeted therapies. This design can be applied more broadly to early-phase combination studies, as it was used in an ongoing study of a melanoma helper peptide vaccine plus novel adjuvant combinations. Clin Cancer Res; 23(23); 7158–64. ©2017 AACR.
A MULTIDISCIPLINARY SPORTS MEDICINE PERFORMANCE MODEL IN ELITE WOMENS INTERNATIONAL SOCCER
Authors: Stephen Boyce, Oliver Davies, Michael McKenna, Andrew White, Mark Dixon, Niall Elliott
Journal: British Journal of Sports Medicine (2017)

Background The traditional sports medicine “backroom” team in elite women's international soccer was comprised of a doctor and physiotherapist(s). Objective To introduce a multidisciplinary sports medicine performance model into elite women's international soccer and assess its impact. Design Prospective observational study. Setting Scotland women's soccer national squad. Participants Elite women international soccer players. Interventions Introducing a sports science physiologist and strength and conditioning coach into the sports medicine team. Main Outcome Measurements To monitor objective measurements and subjective health and wellbeing data on a daily basis at international squad gatherings. Results All players reported to a health and wellbeing assessment in the medical area each morning. The following data was collected: Illness and injury surveillance, Urine hydration status, Body weight, Resting heart rate, Menstrual cycle, Physical objective tests (Sit and reach distance, Knee to wall distance, Thomas test, Counter movement jump height), Health and Wellbeing data (Fatigue status, Stress, Sleep quality, Motivation). The performance indicators were discussed amongst the sports medicine team and concerns regarding a player's health and fitness relayed to the coaching staff. Conclusions Changing a traditional approach to performance and incorporating other professionals skills by working in partnership in a new sports medicine performance model provided an efficient method of determining player's health, wellbeing and fitness on a daily basis allowing discussion within the sports medicine team with any concerns relayed to the coaching staff over performance indicators.
Bortezomib, Bendamustine, and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: Encouraging Activity in the Phase 2 VERTICAL Study.
Authors: Nathan Fowler, Brad S Kahl, Peter Rosen, Jeffrey Matous, Amanda Cashen, Samuel Jacobs, Jeffrey Letzer, Bipinkumar Amin, Michael Williams, Maureen Ross, Sonali Smith, Alfred Saleh, Hongliang Shi, Sudha Parasuraman, Bruce D. Cheson
Journal: Blood (2009)
Association of Incident Amelanotic Melanoma With Phenotypic Characteristics, <i>MC1R</i> Status, and Prior Amelanotic Melanoma
Authors: Steven Vernali, Weston T. Waxweiler, Patrick M. Dillon, Peter A. Kanetsky, Irene Orlow, Li Luo, Klaus J. Busam, Anne Kricker, Bruce K. Armstrong, Hoda Anton-Culver, Stephen B. Gruber, Richard P. Gallagher, Roberto Zanetti, Stefano Rosso, Lidia Sacchetto, Terence Dwyer, Anne E. Cust, David W. Ollila, Colin B. Begg, Marianne Berwick, Nancy E. Thomas
Journal: JAMA Dermatology (2017)

We previously reported that survival is poorer from histopathologically amelanotic than pigmented melanoma because of more advanced stage at diagnosis. Identifying patients at risk of amelanotic melanoma might enable earlier diagnosis and improved survival; however, the phenotypic characteristics and underlying genetics associated with amelanotic melanoma are unknown.
The ‘critical mass’ survey of palliative care programme at ESMO designated centres of integrated oncology and palliative care
Authors: D. Hui, N. Cherny, N. Latino, F. Strasser
Journal: Annals of Oncology (2017)

The ESMO Designated Centres (ESMO-DCs) of Integrated Oncology and Palliative Care (PC) Incentive Programme has grown steadily. We aimed to characterise the level of PC clinical services, education and research at ESMO-DCs.We sent all 184 ESMO-DCs an electronic survey consisting of 78 questions examining the DC characteristics, palliative care clinical programme (structure, processes, and outcomes), primary PC delivery by oncologists, education, research and attitudes and beliefs towards the ESMO-DC programme.The response rate was 83% (152/184). 115 (76%) ESMO-DCs were from Europe, 87 (57%) were tertiary care centres. 136 (90%) had inpatient consultation teams, 135 (89%) had outpatient PC clinics, 107 (71%) had dedicated acute care beds, and 75 (50%) offered community-based PC. An estimated 70% (interquartile range [IQR] 28-80%) of patients with advanced cancer had a PC consultation before death, occurring 90 days before death (median, IQR 40-150 days) for outpatients and 21 days (IQR 14-45 days) for inpatients. 59 (39%) offered PC fellowship programme; 47 (32%) had mandatory PC rotations for oncology fellows. Ninety-nine (65%) had double-boarded palliative oncologists. 118 (78%) of the ESMO-DCs reported that routine symptom screening was offered in the oncology clinic and 30% of patients had documented end-of-life discussions by their oncologists. Most centres (>80%) perceived the ESMO-DC programme to increase their status.The ESMO-DCs had a high level of PC infrastructure and provided access to a large proportion of patients with advanced cancer. The survey supports that the 13 criteria required for ESMO designation set a robust framework for integration, stimulated investment of resources into some palliative care programmes prior to accreditation, and raised the interest about palliative care among clinicians, trainees and patients.
Arginine Methylation Mediated By PRMT5 Has Significant Biological and Clinical Impact in Multiple Myeloma
Authors: Annamaria Gulla, Teru Hideshima, Giada Bianchi, Mariateresa Fulciniti, Mehmet K. Samur, Yu-Tzu Tai, Jun Qi, Takeshi Harada, Eugenio Morelli, Nicola Amodio, Ruben D. Carrasco, Pierosandro Tagliaferri, Nikhil C. Munshi, Pierfrancesco Tassone, Kenneth C. Anderson
Journal: Blood (2016)
Generic ADHD Drug
Authors: Rebecca Voelker
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hypoxic vascular response and ventilation/perfusion matching in end-stage COPD may depend on p22phox
Authors: Chandran Nagaraj, Christoph Tabeling, Bence M. Nagy, Pritesh P. Jain, Leigh M. Marsh, Rita Papp, Michael Pienn, Martin Witzenrath, Bahil Ghanim, Walter Klepetko, E. Kenneth Weir, Stefan Heschl, Grazyna Kwapiszewska, Andrea Olschewski, Horst Olschewski
Journal: European Respiratory Journal (2017)

Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease in which the amount of emphysema and airway disease may be very different between individuals, even in end-stage disease. Emphysema formation may be linked to the involvement of the small pulmonary vessels. The NAPDH oxidase (Nox) family is emerging as a key disease-related factor in vascular diseases, but currently its role in hypoxia-induced pulmonary remodelling in COPD remains unclear. Here we investigate the role of p22phox, a regulatory subunit of Nox, in COPD lungs, hypoxic pulmonary vasoconstriction (HPV), hypoxia-induced pulmonary vascular remodelling and pulmonary hypertension. In COPD, compared to control lungs, p22phox expression was significantly reduced. The expression was correlated positively with mean pulmonary arterial pressure and oxygenation index and negatively with the diffusing capacity of the lung for carbon monoxide (p&lt;0.02). This suggests a role of p22phox in ventilation/perfusion ratio matching, vascular remodelling and loss of perfused lung area. In p22phox -/- mice, HPV was significantly impaired. In the chronic hypoxic setting, lack of p22phox was associated with improved right ventricular function and decreased pulmonary vascular remodelling. p22phox-dependent Nox plays an important role in the COPD phenotype, by its action on phase II HPV and chronic vascular remodelling.